Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 98% confidence The document is a Form S-8 registration statement filed with the SEC to register the offer and sale of additional common shares under the company’s 2025 Stock Option and Incentive Plan and the 2026 Inducement Plan. A Form S-8 is specifically used to register new share issuances under employee benefit plans, which falls under a capital change/share issuance announcement. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-05-29 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Form 8-K reporting the submission of matters to a vote of security holders at the company’s annual meeting, including detailed vote tallies for director elections, auditor ratification, and an amendment to the stock option plan. This matches the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-20 English
10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
Report Publication Announcement Classification · 90% confidence The document is a Form 8-K “Current Report” under Item 2.02 “Results of Operations and Financial Condition” that does not contain the actual financial statements or earnings metrics but rather notes that a press release reporting Q1 2026 results has been issued and is furnished as Exhibit 99.1. The text is under 5,000 characters and simply announces the release and availability of the report. Per the “menu vs meal” rule, this is an announcement of a report’s publication, not the report itself. Therefore it should be classified as a Report Publication Announcement.
2026-05-12 English
ARS - ProMIS Neurosciences Inc. (0001374339) (Filer)
Annual Report
2026-04-09 English
DEF 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
Proxy Solicitation & Information Statement
2026-04-09 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.